Claim Amendments:

1. (Currently amended) A compound of formula:

$$R_{1} \xrightarrow{Y} A \longrightarrow (CH_{2})_{n} N \xrightarrow{R_{2}} \qquad (I)$$

in which:

- A represents a group chosen from the following:

- n is equal to 1 or 2;
- X represents a hydrogen, chlorine or fluorine atom or a methyl or methoxy group;
- Y represents a hydrogen atom or a chlorine or fluorine atom;
- R_1 represents a cyclohexyl group monosubstituted, disubstituted, trisubstituted or tetrasubstituted with a methyl group; a phenyl group monosubstituted or disubstituted with a fluorine or chlorine atom or with a (C_1-C_3) alkoxy or trifluoromethyl group; a cycloheptyl, *tert*-butyl, dicyclopropylmethyl,

bicyclo[3.2.1]octanyl, 4-tetrahydropyranyl, 4-tetrahydrothiopyranyl or 1- or 2-adamantyl group; or R₁ represents a phenyl group, it being understood that, in this case, X or Y is other than hydrogen; or R₁ represents a cyclohexyl group, it being understood that, in this case, X and Y are other than hydrogen;

- R_2 and R_3 form, with the nitrogen atom to which they are bonded, a-5- to 8 membered 7-membered amine ring; a morpholinyl group optionally substituted in positions 3 and 5 with a methyl; or a 4 phenyl-1,2,3,6 tetrahydropyridyl group optionally substituted on the phenyl with a halogen or a trifluoromethyl, $(C_1 - C_4)$ alkyl or $(C_1 - C_4)$ alkoxy group;

and the addition salts of these compounds with pharmaceutically acceptable acids, as well as the solvates and hydrates thereof.

- 2. (Currently amended) A compound according to Claim 1 in which:
- A represents a group chosen from the following:

- n is equal to 1;

- X represents a hydrogen or chlorine atom or a methyl group;
- Y represents a hydrogen or chlorine atom;
- R₁ represents a cyclohexyl group monosubstituted, disubstituted, trisubstituted or tetrasubstituted with a methyl group; a phenyl group monosubstituted or disubstituted with a fluorine or chlorine atom or with a methoxy or trifluoromethyl group; a *tert*-butyl or 1- or 2-adamantyl group; or R₁ represents a phenyl group, it being understood that, in this case, X and Y are other than hydrogen; or else R₁ represents a cyclohexyl group, it being understood that, in this case, X and Y are other than hydrogen;
- R₂ and R₃ form, with the nitrogen atom to which they are bonded, a-6-to 8 membered 7-membered amine ring;

and the addition salts of these compounds with pharmaceutically acceptable acids, as well as the solvates and hydrates thereof.

3. (Currently amended) A compound according to Claim 2 of formula:

$$R_1$$
 A
 CH_2
 N
 $(I.1)$

in which:

- A represents a group chosen from the following:

- X represents a hydrogen or chlorine atom;
- Y represents a hydrogen atom or a chlorine atom;
- R₁ represents a cyclohexyl group monosubstituted, disubstituted, trisubstituted or tetrasubstituted with a methyl group; a phenyl group mono- or disubstituted with a fluorine or chlorine atom or a methoxy group; a *tert*-butyl or 1- or 2-adamantyl group; or R₁ represents a cyclohexyl or phenyl group, it being understood that, in this case, X and Y are other than hydrogen; and the addition salts of these compounds with pharmaceutically acceptable acids, as well as the solvates and hydrates thereof.

- 4. (Previously presented) A compound according to Claim 3 in which A represents the "CH=CH" group, in particular of (Z) configuration.
- 5. (Previously presented) A compound according to Claim 4 in which X represents a chlorine atom and Y represents a hydrogen atom.
- 6. (Previously presented) A compound according to Claim 5 in which R_1 represents a phenyl group monosubstituted or disubstituted with a fluorine or chlorine atom or a methoxy group, and the addition salts of these compounds with pharmaceutically acceptable acids, as well as the solvates and hydrates thereof.
- 7. (Previously presented) A compound:
- 1-[(Z)-3-(2-chloro-3'-fluorobiphenyl-4-yl)propen-2-yl]azepane;
- 1-[(Z)-3-(2-chloro-3'-5'-difluorobiphenyl-4-yl)propen-2-yl]azepane;
- 1-[(Z)-3-(2-chloro-3'-methoxybiphenyl-4-yl)propen-2-yl]azepane; according to Claim 1, as well as the salts with pharmaceutically acceptable acids, solvates and hydrates thereof.
- 8. (Previously presented) A compound 1-[(Z)-3-(2-chloro-3'-methoxybiphenyl-4-yl)propen-2-yl]azepane according to Claim 1, as well as the salts with pharmaceutically acceptable acids, solvates and hydrates thereof.
- 9. (Currently amended) A method for preparing a compound of formula:

$$R_{1} \xrightarrow{Y} A - (CH_{2})_{n} - N \xrightarrow{R_{2}} \qquad (I)$$

according to Claim 1 in which A represents a ¬C≡C¬ group, wherein:

a) either, if n = 1, a Mannich reaction is carried out between the phenylacetylene derivative of formula:

in which R_1 , X and Y are as defined for (I), the formaldehyde and the amine (1) HNR₂R₃, R₂ and R₃ being as defined for (I);

b) or a Suzuki coupling is carried out between the compound of formula:

$$z \xrightarrow{\qquad \qquad } C \equiv C - (CH_2)_n - N \xrightarrow{R_2} \qquad (Ia)$$

in which X, Y, n, R_2 and R_3 are as defined for (I) and Z represents a bromine, an iodine or a trifluoromethanesulphonate (OTf) group, and a boron derivative (2) of formula R_1 -B(OR)₂ in which R_1 is as defined for (I) and R represents a hydrogen atom, an alkyl or aryl group in the presence of a base and a metal catalyst;

c) or, when R_1 represents a cyclohexyl group monosubstituted, disubstituted, trisubstituted or tetrasubstituted with a methyl group; a cycloheptyl, 4-tetrahydropyranyl, 4-tetrahydrothiopyranyl or adamantyl group, a coupling is carried out between the compound (Ia) in which Z represents an iodine or bromine atom and the ketone (3) corresponding to R_1 represented by Cy in the presence of a

base, to give the intermediate compound of formula:

$$C = C - (CH_2) - N = (I')$$

in which X, Y, n, R₂ and R₃ are as defined for (I); said compound (I') then being reduced under selective conditions;

d) or a coupling reaction is carried out between the amine of formula:

$$H-C \equiv C - (CH_2)_n - N \begin{pmatrix} R_2 \\ R_2 \end{pmatrix}$$
 (4)

in which n, R₂ and R₃ are as defined for (I), and the compound of formula:

$$R_1$$
 Z (III)

in which R_1 , X and Y are as defined for (I) and Z represents a bromine or iodine atom or a trifluoromethylsulphonate (triflate or OTf) group.

10. (Currently amended) A method for preparing a compound of formula:

$$R_{1} \xrightarrow{Y} A \longrightarrow (CH_{2})_{n} N \xrightarrow{R_{2}} R_{3} \qquad (I)$$

according to Claim 1 in which A represents a ¬CH=CH¬ group wherein a hydrogenation with nascent hydrogen or in the presence of cyclohexene is carried out on compound (I) in which A represents an acetylene group ¬C=C¬, in order to prepare the ethylenic compound (I) in the form of a mixture of the Z and E isomers, or this hydrogenation is carried out in the presence of a metal catalyst on a support in order to prepare the ethylenic compound (I) in Z form, or alternatively compound (I) in which A represents an acetylene group ¬C=C¬ is reacted with a metal hydride in order to prepare the ethylenic compound (I) in E form.

11. (Currently amended) A method for preparing a compound of formula:

$$R_1 \xrightarrow{Y} A \longrightarrow (CH_2)_n - N \xrightarrow{R_2} R_3 \qquad (I)$$

according to Claim 1 in which A represents a -CH₂-CH₂- group wherein a hydrogenation is carried out on compound (I) in which A represents a -CH=CH− or -C≡C− group.

- 12. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 1.
- 13. (Currently amended) A method for treating psychotic disorders the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment and effective amount of a compound according to Claim 1.
- 14. (Cancelled)
- 15. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 2.
- 16. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 3.
- 17. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 4.
- 18. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 5.
- 19. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 6.
- 20. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 7.

- 21. (Previously presented) A pharmaceutical composition containing as active principle a compound according to Claim 8.
- 22 (Currently amended) A method for treating psychotic disorders the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 2.
- 23. (Currently amended) A method for treating psychotic disorders the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 3.
- 24. (Currently amended) A method for treating psychotic disorders the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 4.
- 25. (Currently amended) A method for treating psychotic disorders the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 5.
- 26. (Currently amended) A method for treating psychotic disorders the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 6.
- 27. (Currently amended) A method for treating psychotic disorders the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 7.

28. (Currently amended) A method for treating psychotic disorders the positive and negative symptoms of schizophrenia which comprises administering to a patient in need of such treatment an effective amount of a compound according to Claim 8.

29 - 35 (Cancelled)